| Description |
1 online resource |
| Bibliography |
Includes bibliographical references and index. |
| Contents |
Front Cover; Neurobiology of Depression: Road to Novel Therapeutics; Copyright; Contents; Contributors; Chapter 1: The Classification of Depression: Embracing Phenotypic Heterogeneity in the Era of the RDoC; Funding; Conflict of Interest; Acknowledgments; References; Chapter 2: The Role of Environmental and Psychosocial Factors in Depression; Introduction; Some Consideration of ``Depression;́́ Depressogenic Factors; Impact of Cognitive Style; Mechanisms Linking Psychosocial Stressors With Depression: The Centrality of Self-Esteem; Depressogenic Stressors; Depression Versus Grief |
|
The Role of PersonalityKeys and Locks: ``Swiss Cheese ́ánd a Lacunae Self-Esteem; Conclusions; Acknowledgments; References; Chapter 3: Gene-Environment Interactions and Epigenetic Mechanisms in Depression; Introduction; Gene x Environment Effects (Candidate Genes); Candidate Genes Within the Serotonergic System; Serotonin Transporter Polymorphism (SLC6A4); GxE Effects in BDNF Function in MDD; GxE Effects in HPA Dysregulation in MDD; GxE Effects: FKBP5 Gene; GxE Effects: CRHR1; Epigenetic Mechanisms Modulating Environmental Effects |
|
Epigenetic Mechanisms Modulating Serotonin Transporter Gene ExpressionEpigenetic Mechanisms Modulating BDNF Gene Expression; Epigenetic Mechanisms in the Regulation of Genes Within the HPA Axis; Genome-Wide GenexEnvironment Effects; Discussion; References; Chapter 4: Pathophysiology of Cognitive Impairment in Depression; Executive Functioning; Working Memory; Memory; References; Further Reading; Chapter 5: Anhedonia in Depression: Mechanisms, Assessment, and Therapeutics; Introduction; Anhedonia: A Brief Historical Context; Anhedonia and Vulnerability to Major Depression |
|
Neural Mechanisms of Anhedonia and DepressionMultifactorial Influences on Striatal Responding and Mood; Environment; Assessment; Therapeutics; Conclusions; Conflict of Interest; Acknowledgments; References; Chapter 6: The Neurotrophic Hypothesis of Depression Revisited: New Insights and Therapeutic Implications; Introduction; Brain-Derived Neurotrophic Factor (BDNF); Role of BDNF in the Effects of Chronic Stress; Regulation of BDNF by Stress; Contribution of BDNF to Stress-Evoked Cytoarchitectural Changes; Contribution of BDNF to Stress-Induced Depressive-like Behavior |
|
Role of BDNF in Antidepressant ActionRegulation of BDNF by Antidepressants; Contribution of BDNF to Antidepressant-Evoked Cytoarchitectural Changes; Influence of BDNF Signaling on Antidepressant-Mediated Behaviors; Clinical Studies; Regulation of BDNF in Depressed Patients; Regulation of BDNF Expression in Response to Antidepressant Treatment; BDNF Polymorphisms; Summary; References; Chapter 7: The Monoamine Hypothesis of Depression Revisited: Could It Mechanistically Novel Antidepressant Strategies?; The Monoamine Hypothesis; Serotonin-Noradrenaline; Dopamine; Withdrawal from Antidepressants |
| Note |
Online resource; title from digital title page (viewed on May 13, 2019). |
| Summary |
Neurobiology of Depression: Road to Novel Therapeutics synthesizes the basic neurobiology of major depressive disorder with discussions on the most recent advances in research, including the interacting pathways implicated in the pathophysiology of MDD, omics technologies, genetic approaches, and the development of novel optogenetic approaches that are changing research perspectives and revolutionizing research into depression. These basic foundational understandings on the neurobiology underlying the disorder, along with a comprehensive summary of the most recent advances in research are combined in this book to aid advanced students and researchers in their understanding of MDD. Depression is one of the most common mental-health disorders caused by a variety of genetic, biological, environmental and psychological factors. Major depressive disorder (MDD) is typically treated with first-line antidepressant agents that primarily target monoamine neurotransmission. However, only approximately one-third of patients with MDD achieve remission following a trial with such an antidepressant. Furthermore, MDD is a heterogeneous phenotype, and new frameworks, such as the NIMH Research Domain Criteria (RDoC) may provide a more accurate, biologically based comprehension of the symptomatic heterogeneity of this devastating illness. |
| Subject |
Depression, Mental -- Pathophysiology.
|
|
Neurobiology.
|
|
HEALTH & FITNESS -- Diseases -- General.
|
|
MEDICAL -- Clinical Medicine.
|
|
MEDICAL -- Diseases.
|
|
MEDICAL -- Evidence-Based Medicine.
|
|
MEDICAL -- Internal Medicine.
|
|
Depression, Mental -- Pathophysiology.
(OCoLC)fst00890949
|
|
Neurobiology. (OCoLC)fst01036315
|
| Added Author |
Quevedo, João, editor.
|
|
Carvalho, André F., editor.
|
|
Zarate, Carlos A., Jr., editor.
|
| Other Form: |
Print version: NEUROBIOLOGY OF DEPRESSION. [Place of publication not identified], ELSEVIER ACADEMIC Press, 2019 0128133333 (OCoLC)1047822936 |
| ISBN |
9780128133347 (electronic book) |
|
0128133341 (electronic book) |
|
9780128133330 |
|
0128133333 |
|
